ARTICLE | Clinical News
CRLX101 regulatory update
May 4, 2015 7:00 AM UTC
FDA granted Fast Track designation to Cerulean’s CRLX101 to treat metastatic renal cell carcinoma (RCC) in combination with Avastin bevacizumab following progression through 2-3 prior lines of therap...